Abstract 951P
Background
Preventing post-operative recurrence and metastasis has become a critical factor in determining the success of hepatectomy for HCC patients (pts). However, the optimal treatment strategy for adjuvant therapy is still under debate. The aim of this study was to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anlotinib and TQB2450 (PD-L1 monoclonal antibody) as adjuvant therapy for pts with HCC at high risk of recurrence after hepatectomy.
Methods
Pts diagnosed as HCC with one or more of the high risk factors after hepatectomy were eligible. Eligible pts received FOLFOX-HAIC (1 cycle) within 1 months after hepatectomy, and on the 2nd day after HAIC, anlotinib (10mg, 4 cycles or 8 cycles) and TQB2450 (1200mg, 4 cycles) were given. The primary endpoint was disease free survival (DFS). Secondary endpoints included overall survival (OS), time to recurrence (TTR) and safety.
Results
At April 18 2023, 72 pts were enrolled and 68 were available to be analyzed. Among them, 34 pts have completed treatment, 26 pts were still on treatment, 8 pts discontinued treatmentearly due to adverse events (AE). 70.6% with liver cirrhosis, 67.7% with MVI, 33.8% with preoperative intrahepatic lesions≥8cm, 7.4% with≥3tumor lesions, 2.9% with tumor thrombus, and 2.9% with preoperative rupture of the tumor or invasion of adjacent organs. At median follow-up of 6.0 (range 0.9-15.1) months, 1 pts relapsed (DFS was 10.87 months).1-year DFS rate was 85.7%, and the longest DFS was over 16.92 months in all pts. The median DFS and OS were not available. Safety profile indicated that 67 pts (98.5%) experienced treatment-related adverse events (TRAEs), and common grade 3 TRAEs included hypertension (8.8%), neutropenia (7.4%) and thrombocytopenia (5.9%).
Conclusions
HAIC combined with anlotinib and TQB2450 as adjuvant therapy for pts with HCC at high risk of recurrence after primary hepatectomy exhibits promising prognosis and tolerable safety profile, and further follow-up is needed for this study to obtain mature data.
Clinical trial identification
NCT05311319.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chia-Tai Tianqing Pharmaceutical Group Co Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18